


LOW PROFILE, YET DURABLE

ULTRA-LOW PROFILE DURABLE^{1,2}




CLINICALLY PROVEN

INCRAFT™
AAA STENT GRAFT SYSTEM

C
Cordis

CLINICALLY PROVEN DURABILITY

LOW PROFILE




LONG TERM CLINICAL DATA

INCRAFT™ AAA Stent Graft System Long-term outcomes

INNOVATION 5-year results²

Event	4 Years	5 Years
Freedom from Endoleak*	100% (39/39)	100% (39/39)
Type Ia	100% (39/39)	97.4% (38/39)
Type Ib	97.4% (38/39)	100% (39/39)
Type III	100% (39/39)	
Stent Graft Patency	97.6% (40/41)	97.4% (38/39)
Freedom from Migrations	100% (38/38)	100% (37/37)
Freedom from Fracture	97.5% (39/40)	97.4% (38/39)
Freedom from Sac Enlargement	89.7% (35/39)	92.1% (35/38)
Freedom from MAE (death, QMI, CVA, renal failure)	82.4% (42/51)	76% (38/50)



* Any Endoleak contains Type I and III endoleaks that are site-reported and CEC adjudicated.

² Endoleg non-patency occurred in one subject at 3YFU and is going at 5YFU.

Both aneurysm enlargement and main body stent-graft migration are defined as being compared to the 30 days baseline CT assessment. One subject did not have 30 days CT and therefore could not be evaluated.

Y Stent-graft fracture is defined as stent skeleton fracture and barb separation and identified through X-ray. Fracture occurred in one subject at 3YFU and is ongoing at 5YFU. For 7 subjects, X-rays were missing however no fractures were reported through other site imaging.

£ 1 death occurred within up to 1 year, 5 within the 2 years timeframe, 2 within 4 years timeframe, 3 within 5 years timeframe, all non-AAA related.

INNOVATION 4 years Publication:

"One of the most important features of the INCRAFT™ AAA Stent Graft System is the precision (proximal and distal) with which it can be deployed. High proximal placement accuracy was achieved during the study"

- "The design of the device permits a high level of deployment precision proximally and distally, maintaining stability with a low rate of migration over long-term follow-up"
- "Durability is maintained despite design attributes that allow reductions in profile comparable to that of a 12F sheath"⁵

INCRAFT™ AAA Stent Graft Post Market Clinical Experience (Muenster)

"Our single center experience has indicated that the INCRAFT™ AAA Stent Graft System achieved generally favorable results although it has been chiefly applied to challenging cases with smaller iliac vessels⁶"

Factors	Group IT n = 17	Group CM n = 24	P
Technical success	17 (100)	24 (100)	
Femoral access	0 (0)/17 (100)	2 (8.3)/22 (91.7)	0.34
Mode of anesthesia			
Regional/spinal	17 (100)/0 (0)	16 (66.7)/8 (33.3)	0.01
Adjunctive iliac intervention	0 (0)	8 (33.3)	0.01
Fluoroscopy time (min)	21 [18 - 31]	19 [16 - 23]	0.11
Contrast (min)	109 [95 - 140]	105 [94 - 115]	0.32
Intraoperative endoleak			
Type I	0 (0)	0 (0)	
Type II	3 (17.6)	6 (25.0)	0.44
Type III	0 (0)	0 (0)	
Type IV	0 (0)	0 (0)	

Categorical data are expressed as numbers (%).

Continuous data are expressed as the means \pm standard deviation or median [interquartile range].

⁶Bolded italic" P-values < 0.05 are considered to be significant.

OPTIMIZED DEPLOYMENT


Advanced graft stability

The suprarenal stent design allows optimal fixation and conformability⁴

Accurate placement

Optimized placement accuracy proximally and distally, with partial repositioning

- To be able to use the maximum available length of the aortic neck
- To avoid covering renal or hypogastric arteries
- To cover the diseased arteries to its maximum



Real time customization

In-procedure bilateral in situ adjustments

- More flexibility with sizing
- Enables accurate anatomy coverage
- Fewer sizes to cover more anatomies⁴

References:

1. Torsello G, Brunkwall J, Scheinert D. Cordis INCRAFT™ ultra-low profile AAA Stent-Graft System. *J Cardiovasc Surg (Torino)*. 2011;52(5):661-667.
2. INNOVATION 5-year results. Torsello G. LINC, 2017.
3. Kannan RY1, Salacinski HJ, Butler PE, et al. Current status of prosthetic bypass grafts: a review. *J Biomed Mater Res B Appl Biomater*. 2005;74(1):570-581.
4. Pratesi G. INCRAFT™ AAA Stent Graft System 2-year clinical data from the INNOVATION Trial. Presented at: Charing Cross International Symposium. April, 2014. London, UK.
5. INNOVATION: Four-year safety and effectiveness of the INCRAFT™ AAA Stent Graft for endovascular repair of abdominal aortic aneurysms. Prof. Pratesi. JCVS.
6. Post Market clinical experience with the INCRAFT™ AAA Stent Graft System for challenging access routes. Torsello G. Elsevier.

For Healthcare Professionals Only.

Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification. Please contact your Cordis representative for additional product availability information. The use of the INCRAFT™ AAA Stent-Graft System requires that physicians be specially trained in endovascular abdominal aortic aneurysm repair techniques, including experience with high resolution fluoroscopy and radiation safety. Cordis will provide training specific to the INCRAFT™ AAA Stent-Graft System. CORDIS, Cordis LOGO and INCRAFT are trademarks of Cordis and may be registered in the US and/or in other countries. All other marks are the property of their respective owners.

© 2026 Cordis. All Rights Reserved. 100620783-2

